NEWS
JOHNSON & JOHNSON RE-BRANDS TO UNITE ITS MEDTECH AND PHARMA SEGMENTS
Johnson & Johnson , with its focus on healthcare innovation and tackling the toughest health challenges , is updating its brand and uniting both its MedTech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare .
“ Our exclusive focus on Innovative Medicine and MedTech solutions enables us to innovate across the full spectrum of healthcare in ways no other company can ,” said Joaquin Duato , Chairman of the Board and Chief Executive Officer . “ Uniting our diverse businesses under an updated Johnson & Johnson brand reflects our unique ability to reimagine healthcare through transformative innovation while staying true to Our Credo values and the level of care that patients and doctors expect of us .”
The announcement marks the next era for Johnson & Johnson , which is leveraging its expertise in innovative medicine and medical technology to prevent , treat and cure complex diseases and introduce solutions that are smarter , less invasive and more personalised .
Moving forward , the company ’ s two segments will be more connected to the Johnson & Johnson brand . Over time , Janssen , the Company ’ s pharmaceutical segment , will be named Johnson & Johnson Innovative Medicine , and the medical technology segment will continue to be named Johnson & Johnson MedTech .
WORLD ' S FIRST DEVICE TO TARGET THE SACROILIAC JOINT REVOLUTIONISES NON-INVASIVE PAIN RELIEF
Pain Relief Technology , a newcomer to the wellness industry , has unveiled the Bax-si , its flagship , eponymous device , designed to provide non-invasive pain relief for those who suffer from lower back discomfort . Their invention comes at a time when back pain relief products are seeing a surge in demand , with many adults and seniors seeking efficient , home-based solutions to their back muscle inflammation and sacroiliac joint-related issues .
The unique selling point of the Bax-si is its focus on opening the sacroiliac joint , thus relieving pressure and discomfort in the lower back region .
As per the company ' s testimonials , no other device in the market today offers this unique method of offering sacroiliac joint pain relief . The Bax-si is an FSA / HSA eligible product .
The Bax-si offers a customisable approach , with the product including two silicone gel wave heads catering to various intensity needs , allowing users to tailor treatment to suit their comfort levels .
The device is compact and portable , coming with a travel bag , allowing users to continue their lower back pain treatment at home or on the go . The product also touts ease of use and hygienic maintenance – with a simple switch-out design – making it a convenient option for a busy lifestyle .
www . intelligenthealth . tech 9